LSTA

Lisata Therapeutics, Inc. (LSTA) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide (LSTA1), an investigational therapy designed to enhance the delivery of anti-cancer drugs to solid tumors by activating the CendR active transport pathway. The company is currently conducting Phase 2 clinical studies for certepetide in various solid tumors, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, and glioblastoma multiforme.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. Total liabilities were $4.6 million as of June 30, 2024.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 11.6% year-over-year for the six months ended June 30, 2024 ($12.1M vs. $13.7M).
  • R&D Expenses: Decreased by 7.9% ($5.8M vs. $6.3M), driven by reduced spend on the completed Phase 2b ASCEND trial and lower CMC costs, partially offset by enrollment costs for the Phase 2a Bolster trial.
  • G&A Expenses: Decreased by 14.9% ($6.3M vs. $7.4M), primarily due to the absence of one-time severance costs incurred in the prior year and reduced equity compensation expense.
• Liquidity Position: While cash and cash equivalents increased to $28.3M from $22.6M at year-end 2023, total liquidity (including marketable securities) decreased to $38.3M from $54.7M at December 31, 2023, due to the net sale of marketable securities to fund operations.
• Investment Income: Investment income decreased to $1.1M for the six months ended June 30, 2024, compared to $1.3M in the prior year period.

Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management believes current cash and marketable securities are sufficient to fund operations for at least the next 12 months. The company may seek additional capital through equity/debt issuances, partnerships, or asset sales.
• ATM Agreement: The company has an "At The Market" offering agreement but was subject to the "Baby Shelf Limitation" (limiting sales to one-third of public float) as of the filing date. No shares were issued under this agreement in Q2 2024.
• Settlement of Litigation: In March 2024, the company settled a legal dispute with Lingmed Limited for $0.5 million, paid in April 2024. Lingmed retains a right to 5% of future milestone payments from the Qilu license agreement plus a $250,000 payment on the first future milestone.
• Tax Incentives: The company sold $8.9M of New Jersey Net Operating Losses (NOLs) in March 2024 for net proceeds of $0.7M, recording a $0.8M deferred tax benefit. Additionally, the Australian subsidiary received a $0.9M tax refund in July 2024.
• Risks: Key risks include the ability to secure sufficient capital, the success of ongoing clinical trials, regulatory approvals, and the potential for dilution from future equity financing.

Key Facts for Investor Verification

• Cash Runway: Verify the 12-month liquidity projection against current burn rates, noting the reduction in total liquidity from $54.7M to $38.3M over the last six months.
• Clinical Progress: Monitor enrollment and data readouts for the Phase 2a Bolster trial and other ongoing Phase 2 studies in mPDAC and other solid tumors.
• Future Milestone Obligations: Review the terms of the Qilu license agreement and the Lingmed settlement, specifically the 5% royalty on future milestones and the $250k upfront milestone payment obligation.
• Capital Raising Constraints: Assess the impact of the "Baby Shelf Limitation" on the company's ability to raise capital via its ATM facility until public float exceeds $75 million.
• Equity Dilution: Note the significant number of outstanding stock options (1.45M) and warrants (1.42M) which could dilute shareholders upon exercise.